Connect with us

Technology

Cryoport Reports First Quarter 2026 Financial Results

Published

on

First quarter revenue grew 16% year-over-year to $47.8 millionCommercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting continued expansion in approved CGT programsLife Sciences Services revenue increased 18% year-over-year, led by 21% growth in BioStorage/BioServices Life Sciences Products revenue increased 15% year-over-year, driven by strong demand for cryogenic systems Supporting a record 766 global clinical trials and 21 commercially approved CGTs as of March 31, 2026Company raises full-year revenue guidance to $192 million – $196 million

NASHVILLE, Tenn., May 4, 2026 /PRNewswire/ — Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its first quarter (Q1) of 2026.

Jerrell Shelton, CEO of Cryoport, commented, “Cryoport delivered a strong start to 2026 with first-quarter revenue of $47.8 million, up 16% year-over-year, reflecting a continuation of our momentum over the past several quarters across our integrated services and products platform. Revenue in support of commercial Cell and Gene Therapies (CGT) grew 26% to $9.1 million, while clinical trial support revenue grew 18% to $12.9 million. We continue to support one of the industry’s broadest CGT pipelines, and our leadership across both clinical and commercial programs positions us well for sustainable growth.

“Our Life Sciences Services segment delivered another strong quarter, with revenue increasing 18% year-over-year, including 21% growth in BioStorage/BioServices. This performance reflects the increasing scope and complexity of the Cell & Gene Therapy programs we support and underscores the critical role we play in supporting our clients with our integrated, temperature-controlled supply chain services.

“Our Life Sciences Products segment also performed very well, generating 15% revenue growth, driven by global demand for MVE Biological Solutions’ cryogenic systems. MVE continues to innovate and further solidify its position as the global leader in high-quality cryogenic systems.

“This growth across both our reporting segments, combined with solid gross margins and continued operational discipline, drove a $2.2 million year-over-year improvement in adjusted EBITDA from continuing operations, advancing us meaningfully along our “pathway to profitability.”

“Looking ahead, we see multiple growth catalysts extending beyond 2026, including the planned launch of BioServices operations at our Global Supply Chain Center in Paris, France in the third quarter, and the planned opening of our new Global Supply Chain Center in Santa Ana, California in the fourth quarter. These strategic investments expand our global footprint in key geographies and further strengthen our ability to support the advancement and commercialization of life-saving therapies globally. Reflecting on our strong performance in the first quarter and increased visibility into the remainder of the year, we are raising our full-year revenue guidance to $192 million to $196 million,” concluded Mr. Shelton.

The following table presents Q1 2026 revenue compared with Q1 2025:

Cryoport, Inc. and Subsidiaries

Revenue 

Three Months Ended
March 31,
(unaudited)

(in thousands)

2026

2025

% Change

Life Sciences Services

$              26,898

$              22,865

18 %

BioLogistics Solutions

21,668

18,531

17 %

BioStorage/BioServices 

5,230

4,334

21 %

Life Sciences Products

$              20,900

$              18,175

15 %

Total Revenue

$              47,798

$              41,040

16 %

BioLogistics Solutions revenue increased 17% year-over-year in Q1 2026, driven by increasing customer activity, continued commercial product maturation, and clinical advancement within the CGT market. BioStorage/BioServices revenue grew 21% year-over-year, reflecting strong demand for our expanded, integrated services offering, which provides seamless, secure handling of temperature-sensitive materials across our global network.

Revenue from the support of commercial CGTs increased 26% year-over-year to $9.1 million and as of March 31, 2026, the number of commercial therapies we support increased to 21.

As of March 31, 2026, Cryoport supported a total of 766 global clinical trials, a net increase of 55 clinical trials over March 31, 2025, with 91 of these clinical trials in Phase 3. The number of trials by phase and region are as follows: 

Cryoport Supported Clinical Trials by Phase

Clinical Trials

March 31,

2024

2025

2026

Phase 1

286

304

318

Phase 2

312

328

357

Phase 3

77

79

91

Total

675

711

766

Cryoport Supported Clinical Trials by Region

Clinical Trials

March 31,

2024

2025

2026

Americas

518

544

569

EMEA

112

118

143

APAC

45

49

54

Total

675

711

766

In Q1 2026, four Biologics License Applications (BLA) / Marketing Authorization Applications (MAA) filings occurred. During the first quarter, Cryoport’s customer, Rocket Pharmaceuticals, received U.S. Food and Drug Administration (FDA) accelerated approval for their gene therapy KRESLADI™ for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I). Severe LAD-I is an ultra-rare, life-threatening pediatric genetic immunodeficiency characterized by recurrent infections and high early-childhood mortality without treatment. For the balance of 2026, we anticipate another 10 possible BLA/MAA application filings and 8 additional new therapy approvals.

Operational milestones

Life Sciences Services

BioServices launch at our Global Supply Chain Center in Paris, France, expected in Q3, 2026.Continued progress toward the launch of our state-of-the-art Global Supply Chain Center in Santa Ana, California, expected in Q4, 2026.First cryopreserved clinical trial patient materials shipped in Q1 for two of our clients at our IntegriCell® facilities in Belgium and the U.S.Cryoport Systems named Best Logistics & Supply Chain Management Supplier – Digital Technology & Software at the 2026 Asia Pacific Biopharma Excellence Awards in Singapore.

Life Sciences Products

MVE Biological Solutions (MVE) introduced its new Fusion® 800 Series, the next evolution of MVE’s patented, award-winning Fusion technology, a self-sustaining cryogenic freezer that eliminates the need for a continuous liquid nitrogen (LN₂) supply feed, delivering exceptional reliability, safety, and sustainability in a compact footprint designed for space-constrained environments.Release of MVE HE (High Efficiency) cryogenic storage systems series integrated with the new MVE CryoVerse™ Connect Controller platform.

Financial Highlights

On June 11, 2025, the Company completed the divestiture of its CRYOPDP specialty courier business to DHL Group as part of a strategic partnership. The results of CRYOPDP, a former business within Cryoport’s Life Sciences Services segment, are presented as discontinued operations for all periods and are excluded from the non-GAAP financial measures in this release.

Revenue

Total revenue for Q1 2026 was $47.8 million, compared to $41.0 million for Q1 2025, a year-over-year increase of 16%, or $6.8 million. Life Sciences Services revenue for Q1 2026 (representing 56% of our total revenue) was $26.9 million, compared to $22.9 million for Q1 2025, up 18% year-over-year, including BioStorage/BioServices revenue of $5.2 million, up 21% year-over-year. Life Sciences Products revenue for Q1 2026 (representing 44% of our total revenue) was $20.9 million, compared to $18.2 million for Q1 2025, up 15% year-over-year.

Gross Margin

Total gross margin was 45.8% for Q1 2026, compared to 45.4% for Q1 2025. Gross margin for Life Sciences Services was 48.9% for Q1 2026, compared to 47.9% for Q1 2025. Gross margin for Life Sciences Products was 41.9% for Q1 2026, compared to 42.3% for Q1 2025.

Operating Costs and Expenses

Operating costs and expenses were $31.5 million for Q1 2026, compared to $25.8 million for Q1 2025.

Loss from Continuing Operations

Loss from continuing operations was $9.4 million for Q1 2026, compared to a loss of $6.7 million for Q1 2025.

Net Loss – including Discontinued Operations

Net loss was $10.5 million for Q1 2026, compared to net loss of $12.0 million for Q1 2025.Net loss attributable to common stockholders for Q1 2026 was $12.5 million, or $0.25 per share, compared to net loss attributable to common stockholders of $14.0 million, or $0.28 per share for Q1 2025.

Adjusted EBITDA from Continuing Operations

Adjusted EBITDA from continuing operations was a negative $0.6 million for Q1 2026, compared to a negative $2.8 million for Q1 2025.

Cash, Cash equivalents, and Short-Term Investments

Cryoport held $403.6 million in cash, cash equivalents, and short-term investments as of March 31, 2026.

Note: All reconciliations of GAAP to adjusted (non-GAAP) figures above are detailed in the reconciliation tables included later in the press release.

Additional Information

Further information on Cryoport’s financial results is included in the attached condensed consolidated balance sheets and statements of operations, and additional explanations of Cryoport’s financial performance are provided in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which is expected to be filed with the SEC on May 4, 2026. Additionally, the full report will be available in the SEC Filings section of the Investor Relations section of Cryoport’s website at www.cryoportinc.com.

Earnings Conference Call Information

IMPORTANT INFORMATION: In addition to the earnings release, a document titled “Cryoport First Quarter 2026 in Review”, providing a review of Cryoport’s business update, will be issued at 4:05 p.m. ET on Monday, May 4, 2026. The document is designed to be read in advance of the questions and answers conference call and will be accessible at https://ir.cryoportinc.com/news-events/ir-calendar.

Cryoport management will host a conference call at 5:00 p.m. ET on May 4, 2026. The conference call will be in the format of a questions and answers session and will address any queries investors have regarding the Company’s reported results. A slide deck will accompany the call.

Conference Call Information

Date:

Monday, May 4, 2026

Time:

5:00 p.m. ET

Dial-in numbers:

1-800-717-1738 (U.S.), 1-646-307-1865 (International)

Confirmation code:

Request the “Cryoport Call” or Conference ID: 1191652

Live webcast:

‘Investor Relations’ section at www.cryoportinc.com or click here.


Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.

The questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor Relations section of the Company’s website at www.cryoportinc.com for a limited time. To access the replay of the questions and answers click here. A dial-in replay of the call will also be available to those interested, until May 11, 2026. To access the replay, dial 1-844-512-2921 (United States) or 1-412-317-6671 (International) and enter replay entry code: 1191652#.

About Cryoport, Inc.

Cryoport, Inc. (Nasdaq: CYRX) is a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are “Enabling the Future of Medicine™.” 

Headquartered in Nashville, Tennessee, our company maintains a strong global presence with operations across the Americas, EMEA, and APAC.

For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at https://x.com/cryoport for live updates.

Forward-Looking Statements

Statements in this press release which are not purely historical, including statements regarding the Company’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company’s industry, business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as the Company’s outlook and guidance for full-year 2026 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Company operates, the Company’s plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, the Company’s expectations about future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines of treatment approved with respect to the products of the Company’s clients. Forward-looking statements also include those related to the Company’s expectations about future benefits relating to the CRYOPDP divestiture and strategic partnership with DHL (collectively, the “DHL Transaction”), the Company’s plans regarding its Global Supply Chain Centers, including expected timing of future openings, the Company’s plans and expectations relating to its strategic pivot to expand its global partnerships, and the Company’s expectation of revenue contribution from IntegriCell’s cryopreservation service centers throughout 2026. It is important to note that the Company’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effects of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, tariffs and other trade restrictions, foreign currency fluctuations, trends in the products markets, any U.S federal government shutdown, variations in the Company’s cash flow, market acceptance risks, and technical development risks. Additional risks and uncertainties relating to the DHL Transaction include, but are not limited to, the risk that any disruption resulting from the DHL Transaction may adversely affect our businesses and business relationships, including with employees and suppliers. The Company’s business could be affected by other factors discussed in the Company’s SEC reports, including in the “Risk Factors” section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and the Company cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, the Company disclaims any obligation and does not undertake to update or revise any forward-looking statements in this press release.

Cryoport, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

Three Months Ended
March 31,
(unaudited)

(in thousands, except share and per share data)

2026

2025

Revenue

Life Sciences Services revenue

$                   26,898

$                   22,865

Life Sciences Products revenue

20,900

18,175

Total revenue

47,798

41,040

Cost of revenue:

Cost of services revenue

13,747

11,920

Cost of products revenue

12,138

10,479

Total cost of revenue

25,885

22,399

Gross margin

21,913

18,641

Operating costs and expenses:

Selling, general and administrative

27,620

21,901

Engineering and development

3,907

3,934

Total operating costs and expenses:

31,527

25,835

Loss from operations

(9,614)

(7,194)

Other income (expense):

Investment income

3,090

1,573

Interest expense

(432)

(583)

Other expense, net

(2,368)

(300)

Loss before provision for income taxes

(9,324)

(6,504)

Provision for income taxes

(108)

(234)

Loss from continuing operations

$                   (9,432)

$                   (6,738)

Loss from discontinued operations, net

(1,112)

(5,243)

Net loss

$                 (10,544)

$                 (11,981)

Paid-in-kind dividend on Series C convertible preferred stock

(2,000)

(2,000)

Net loss attributable to common stockholders

$                 (12,544)

$                 (13,981)

Net loss per share attributable to common stockholders – basic and diluted

$                     (0.25)

$                     (0.28)

Weighted average common shares issued and outstanding – basic and diluted

49,897,817

49,947,012

 

Cryoport, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

March 31,

December 31,

2026

2025

(in thousands)

(unaudited)

Current assets

Cash and cash equivalents

$                     272,912

$                     250,494

Short-term investments

130,722

160,714

Accounts receivable, net

39,004

33,359

Inventories

21,750

23,188

Prepaid expenses and other current assets

6,147

8,419

Total current assets

470,535

476,174

Property and equipment, net

89,805

85,448

Operating lease right-of-use assets

39,299

39,720

Intangible assets, net

138,721

138,082

Goodwill

22,137

22,400

Deposits

2,046

2,092

Deferred tax assets

1,066

1,073

 Total assets 

$                     763,609

$                     764,989

Current liabilities

Accounts payable and other accrued expenses                                         

$                       15,937

$                       15,283

Accrued compensation and related expenses

17,007

12,980

Deferred revenue

2,314

943

Current portion of operating lease liabilities

3,641

4,133

Current portion of finance lease liabilities

419

422

Current portion of convertible senior notes, net

185,390

185,094

Current portion of notes payable

159

163

Total current liabilities

224,867

219,018

Notes payable, net

1,027

1,087

Operating lease liabilities, net

39,173

39,078

Finance lease liabilities, net

680

741

Deferred tax liabilities

1,580

1,354

Other long-term liabilities

663

444

Contingent consideration

630

629

Total liabilities

268,620

262,351

Total stockholders’ equity

494,989

502,638

Total liabilities and stockholders’ equity

$                     763,609

$                     764,989

Note Regarding Use of Non-GAAP Financial Measures

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measure of financial performance as defined in Regulation G of the Securities Exchange Act of 1934 is included in this release: adjusted EBITDA from continuing operations. Non-GAAP financial measures are not calculated in accordance with GAAP, are not based on any comprehensive set of accounting rules or principles and may be different from non-GAAP financial measures presented by other companies. Non-GAAP financial measures, including adjusted EBITDA from continuing operations, should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.

Adjusted EBITDA from continuing operations is defined as loss from continuing operations adjusted for net interest expense, income taxes, depreciation and amortization expense, stock-based compensation expense, acquisition and integration costs, cost reduction initiatives, investment income, unrealized loss on investments, foreign currency loss, changes in fair value of contingent consideration and charges or gains resulting from non-recurring events, as applicable.

Management believes that adjusted EBITDA from continuing operations provides a useful measure of Cryoport’s operating results, a meaningful comparison with historical results and with the results of other companies, and insight into Cryoport’s ongoing operating performance. Further, management and the Company’s board of directors utilize adjusted EBITDA from continuing operations to gain a better understanding of Cryoport’s comparative operating performance from period to period and as a basis for planning and forecasting future periods. Adjusted EBITDA from continuing operations is also a significant performance measure used by Cryoport in connection with its incentive compensation programs. Management believes adjusted EBITDA from continuing operations, when read in conjunction with Cryoport’s GAAP financials, is useful to investors because it provides a basis for meaningful period-to-period comparisons of Cryoport’s ongoing operating results, including results of operations, against investor and analyst financial models, helps identify trends in Cryoport’s underlying business and in performing related trend analyses, and it provides a better understanding of how management plans and measures Cryoport’s underlying business.

Cryoport, Inc. and Subsidiaries

Reconciliation of GAAP loss from continuing operations to adjusted EBITDA

(unaudited)

Three Months Ended
March 31,

2026

2025

(in thousands)

GAAP loss from continuing operations

$          (9,432)

$            (6,738)

Non-GAAP adjustments to loss:

Depreciation and amortization expense

6,402

6,134

Acquisition and integration costs

—

1

Cost reduction initiatives

—

216

Investment income

(3,090)

(1,573)

Unrealized loss on investments

2,105

193

Foreign currency loss

454

245

Interest expense, net

432

583

Stock-based compensation expense

2,395

3,064

Change in fair value of contingent consideration

15

(5,178)

Income taxes

108

234

Adjusted EBITDA from continuing operations

$             (611)

$            (2,819)

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-reports-first-quarter-2026-financial-results-302761639.html

SOURCE Cryoport, Inc.

Continue Reading

Technology

SBC and V&V Group Announce Strategic Consolidation of Technology and AI Capabilities into a Joint-Venture Platform

Published

on

By

14 tax-technology products and intellectual assets came together under a common AI-native integration layer, creating an integrated platform spanning transfer pricing, corporate tax, GST, e-invoicing, audit and suite of accounting products. Combined businesses served 1,500–2,000 clients, including over 350 multinational groups, and brought together nearly 500 professionals, with plans to expand into four to five jurisdictions within 24 months

HYDERABAD, India, Oct. 23, 2026 /PRNewswire/ — Steadfast Business Consulting (SBC), a Hyderabad-headquartered international tax, transfer pricing and tax-technology group, and V&V Group, a Bengaluru-based GST and audit-technology group, announced a strategic consolidation of their technology assets and artificial intelligence (AI) capabilities into a joint-venture technology platform. The initiative marks a significant step towards building an Indian-owned, AI-enabled technology enterprise that combines deep tax expertise, proprietary software and intelligent automation to serve businesses and professional services firms across global markets.

The consolidation brings together 14 technology products and intellectual assets spanning transfer pricing, corporate taxation, GST, e-invoicing, audit, bookkeeping and regulatory compliance. Together, the two organisations serve approximately 1,500–2,000 clients, including more than 350 multinational groups, and brings together nearly 500 professionals, comprising 40–50 chartered accountants and 40–50 engineers. Their services businesses across India, the UAE, the United States and Europe are positioned to serve as the platform’s first customers and international distribution channel.

The combined portfolio includes SBC’s TP Doc Gen AI (TAIGA), TaxMate, FixTag, SBC Track and ROC Data, alongside V&V Group’s GSTZen, WeAudit, DeskAudit, Papilio and the Tidy suite. The common AI-native integration layer is designed to connect these products, streamline workflows and reduce duplication in technology development, data infrastructure and service delivery.

Commenting on the announcement, CA Mithilesh Reddy, Founder & Managing Partner, SBC, said, “Indian firms never lacked talent. We lacked scale and ownership of our tools. This combination gave us both. By bringing together our domain expertise, proprietary technologies and AI capabilities, we took an important step towards building a globally competitive, Indian-owned technology enterprise. Our vision was to move beyond traditional consulting models and create a platform where every service engagement benefited from our own technology, enabling us to deliver greater efficiency, consistency and value to businesses worldwide.”

The combined technology estate included 51 AI agents, of which 44 are operational. The proposed common AI layer brings together regulatory knowledge, tax laws, rulings, comparables and financial data to support automation across document preparation, data processing, reporting and audit-related workflows. The architecture is designed to integrate with client enterprise resource planning systems, India’s GST and e-invoicing infrastructure, and relevant data providers.

The platform follows a human-led decision-making model: AI executed repetitive and data-intensive tasks, while qualified professionals retained responsibility for interpretation, review and final decisions. This approach sought to combine the speed and scalability of automation with professional judgement, accountability and regulatory expertise.

Vinay Thyagaraj, Co-founder, V&V Group and GSTZen, said, “Our GST, e-invoicing and audit engines already supported Indian businesses in managing their everyday compliance requirements. Bringing these capabilities together with SBC’s expertise in international taxation and transfer pricing created an opportunity to build a more comprehensive technology platform. With one AI layer and a wider global channel, we aimed to transform proven India-built solutions into scalable products that businesses and professional services firms across the world could use. Our focus remained on using technology to simplify complexity while keeping qualified professionals at the centre of decision-making.”

The organisations outlined a four-phase integration roadmap spanning 24 months. The initial 90 days focused on establishing joint technology leadership, a common data infrastructure and an integrated product roadmap. The next phase envisaged cross-selling opportunities across the combined client base and the establishment of a shared delivery centre. Within 12 months, the technology joint venture planned to introduce new products, including UAE e-invoicing, WeAudit AI and TidyBooks AI. The final phase targeted operations across four to five jurisdictions within 24 months.

TidyBooks AI is envisioned as an integrated platform connecting invoicing, accounting, financial statements, audit files and transfer pricing documentation. The roadmap also includes expanding the technology portfolio into global VAT and e-invoicing requirements, with Dubai positioned as a regional hub for the Gulf Cooperation Council market.

The consolidation is expected to generate operational efficiencies through a shared engineering team, common data stack, unified AI gateway, integrated delivery infrastructure and a single go-to-market strategy. The model followed a ‘build once, deploy everywhere’ approach, allowing the organisations to scale technology across their combined client base without duplicating development efforts.

Beyond serving their own clients, the organisations envisage a white-label and subscription-based delivery model that enabled other professional and consulting firms to access the platform under their own brands. The approach was intended to help smaller and mid-sized firms adopt advanced technology without having to independently develop and maintain complex software infrastructure.

The initiative also seeks to strengthen India’s position as a global hub for technology-enabled professional services. By combining its accounting expertise, engineering talent and cost-efficient delivery capabilities, the group aimed to export technology-led tax and compliance solutions to international markets while creating opportunities for professionals skilled in AI, taxation and regulatory technology.

About SBC: SBC is an international tax, transfer pricing and tax-technology group with operations in Hyderabad and Dubai and a presence in the United States. It serves more than 350 multinational groups across international taxation, transfer pricing, Advance Pricing Agreements, UAE corporate tax, Pillar Two, virtual CFO services and Global Capability Centre advisory. Its technology portfolio includes TP Doc Gen AI (TAIGA) and TaxMate. SBC is a member of Kreston Global, an international network spanning more than 120 countries. Website: steadfastconsultants.in 

About V&V Group and GSTZen: V&V Group, co-founded by Vinay Thyagaraj and CA Venugopal Gella, is a Bengaluru-based technology group specializing in GST, e-invoicing, audit automation, bookkeeping, VAT and customs technology. Its portfolio includes GSTZen, WeAudit, DeskAudit and the Tidy suite of products. The group focuses on simplifying tax compliance, financial reporting and audit processes through technology-enabled solutions. Website: gstzen.in

 

 

View original content:https://www.prnewswire.com/in/news-releases/sbc-and-vv-group-announce-strategic-consolidation-of-technology-and-ai-capabilities-into-a-joint-venture-platform-302917845.html

Continue Reading

Technology

Studsvik and ReNu Industries partner to bring inDRUM waste treatment technology to Fukushima

Published

on

By

Studsvik AB and ReNu Industries Inc. will adapt Studsvik’s inDRUM technology for radioactive waste treatment to Japanese conditions, with the aim of building a pilot plant in Fukushima. Studsvik’s Japanese subsidiary, Studsvik Japan, Ltd., and ReNu signed an agreement on technical advisory services at Studsvik’s headquarters in Nyköping on 21 October 2026.

NYKÖPING, Sweden, Oct. 23, 2026 /PRNewswire/ — Under the agreement, Studsvik will provide ReNu with technical information and advice on design conditions for a Japanese version of inDRUM. ReNu will design a pilot plant adapted to Japan’s seismic and regulatory requirements and to the characteristics of the waste to be treated.

The partnership is the first step in the model Studsvik has chosen for taking inDRUM to international markets. Studsvik will build and operate its own inDRUM facilities in Sweden, while abroad it will license the technology and work with local partners that design, build and operate the plants.

inDRUM, developed and patented by Studsvik, treats radioactive waste inside sealed drums. Each drum is placed in a treatment unit and heated under a nitrogen blanket, which removes free liquids, breaks down organic material and leaves a stable residue suitable for long-term storage and disposal. Because the drums are neither opened nor sorted, worker exposure and manual handling are minimised. For spent ion-exchange resins and similar wastes, volume can be reduced by up to 90 per cent. Studsvik operates a full-scale inDRUM demonstration facility in Nyköping and is advancing the adoption of inDRUM for the treatment of radioactive waste from the European Spallation Source (ESS) in Lund.

Decommissioning of the Fukushima Daiichi Nuclear Power Plant is expected to take 30–40 years, and the decommissioning of other nuclear power plants in Japan is gathering pace. At the same time, Japan is restarting reactors shut down after 2011, which increases the need for waste treatment and for other services Studsvik provides. Reducing and stabilising the volume of radioactive waste is a long-term challenge in this work.

ReNu has been awarded up to JPY 700 million (approximately USD 4.4 million) under the Subsidy for Projects Promoting Practical Development for Regional Reconstruction, implemented by Fukushima Prefecture under the Japanese Government’s Fukushima reconstruction initiative, to develop a radioactive waste treatment pilot plant in Fukushima. ReNu aims to establish the basic design conditions for the Japanese version of inDRUM during fiscal year 2026, which ends in March 2027, and, subject to the necessary agreements, to complete the pilot plant in fiscal year 2028.

Building on the Fukushima project, Studsvik and ReNu will explore deploying inDRUM elsewhere in Japan and in Asia, as well as broader cooperation in nuclear engineering, including fusion.

“Fukushima will need radioactive waste treatment for decades. ReNu is based in Okuma, the town that hosts the plant, and brings the local knowledge needed to adapt inDRUM to Japanese conditions. Fukushima is our starting point in Japan and in Asia,” says Karl Thedéen, President and CEO, Studsvik.

“Studsvik Japan will coordinate the Studsvik Group’s experts and support ReNu as it develops the Japanese version of inDRUM,” says Masatoshi Yamasaki, President and Representative Director, Studsvik Japan.

“Decommissioning Fukushima requires technology proven around the world, re-engineered to fit Japan’s regulations and site conditions and implemented with local hands. Through our technical collaboration with Studsvik, ReNu will adapt inDRUM to Japanese regulatory and site requirements. We intend to build on our experience in Fukushima to pursue opportunities elsewhere in Japan and overseas,” says Ryohei Takahashi, CEO, ReNu Industries Inc.

The agreement is not expected to have a financial impact of such materiality that it significantly affects Studsvik Group’s results during 2026–2027.

For more information, please contact:

Studsvik AB, Media Relations: media.relations@studsvik.com 

ReNu Industries Inc., Public Relations: info@renu-industries.com 

About Studsvik

Studsvik is an independent nuclear technology company active across the full nuclear lifecycle, from new build development to existing fleet services, operations support and decommissioning. It is a leading supplier of vendor-independent reactor analysis software, and its hot cell laboratories in Nyköping test fuel and materials for fission and fusion applications worldwide. Studsvik also provides radiation protection services and technology for treating radioactive waste, and handles and packages radioisotopes for healthcare and industry. ReFirm is Studsvik’s platform for new nuclear development in Sweden. Founded in 1947 as the centre of Sweden’s national nuclear programme, Studsvik today serves operators, fuel vendors, technology developers and regulators in more than 20 countries, has approximately 540 employees in six countries, and is listed on Nasdaq Stockholm (SVIK).

www.studsvik.com  https://www.linkedin.com/company/studsvik/

About ReNu Industries

ReNu Industries Inc. is a nuclear engineering start-up founded in December 2025 and headquartered in Okuma Town, Futaba District, Fukushima Prefecture, Japan. Through the business succession of local nuclear suppliers and the introduction of advanced technologies from overseas partners and universities, ReNu works to rebuild the nuclear supply chain and accelerate decommissioning. ReNu has raised seed funding from leading Japanese venture capital firms including Spiral Capital, Miraisozo Investments, Mitsubishi UFJ Capital, Fukui Capital Partners and Joyo Capital Partners.

Media Relations
media.relations@studsvik.com 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/studsvik-ab/r/studsvik-and-renu-industries-partner-to-bring-indrum-waste-treatment-technology-to-fukushima,c4413974

The following files are available for download:

https://mb.cision.com/Public/4019/4413974/85e3330f75e328d9.pdf

Press Release Studsvik and ReNu Industries partner to bring inDRUM waste treatment technology to Fukushima October 2026

https://news.cision.com/studsvik-ab/i/renu-studsvik,c3575245

ReNu Studsvik

View original content:https://www.prnewswire.com/apac/news-releases/studsvik-and-renu-industries-partner-to-bring-indrum-waste-treatment-technology-to-fukushima-302917858.html

SOURCE Studsvik AB

Continue Reading

Technology

Securitas AB Interim Report Q3 2026 | January-September

Published

on

By

STOCKHOLM, Oct. 23, 2026 /PRNewswire/ — 

July–September 2026

Total sales MSEK 38 566 (38 521)Organic sales growth 0 percent (3)Adjusted organic sales growth, 3 percent (4)*Real sales growth within technology and solutions 6 percent (4)Operating income before amortization MSEK 3 161 (3 107)Operating margin 8.2 percent (8.1)Adjusted operating margin, 8.2 percent (8.3)*Items affecting comparability (IAC) MSEK –36 (–1 527) Earnings per share, SEK 3.68 (1.09)Earnings per share before IAC, SEK 3.28 (3.34)Cash flow from operating activities 82 percent (106)

January–September 2026

Total sales MSEK 112 620 (116 691)Organic sales growth 0 percent (4)Adjusted organic sales growth, 3 ­percent (4)*Real sales growth within technology and solutions 5 percent (5)Operating income before ­amortization MSEK 8 444 (8 430)Operating margin 7.5 percent (7.2)Adjusted operating margin, 7.6 ­percent (7.5)*Items affecting comparability (IAC) MSEK 102 (–1 770) whereof MSEK 223 (–5) related to divestitures Earnings per share, SEK 9.36 (5.95)Earnings per share before IAC, SEK 8.69 (8.48)Cash flow from operating activities 71 ­percent (74)Net debt/EBITDA ratio 2.1 (2.2) 

*A new key ratio, operating margin adjusted for the government business within SCIS in the process of being closed down, was added as of the second quarter 2025. A new key ratio, organic sales growth adjusted for the same business, was added as of the third quarter 2025. Refer to note 5 for further information.

Comments from the President and CEO

“Solid performance supported by technology momentum”

Organic sales growth in the third quarter was 3 percent, adjusted for the close-down of the SCIS govern­ment business. The Technology and Guarding business units in North America delivered solid growth, while lower activity in the airport business weighed on organic sales growth in Europe. 

Real sales growth in technology and solutions was 6 percent in the third quarter. The commercial momentum in our global technology business remained healthy, as installation order intake and backlog continued to grow, with record-high installation order intake in North America and Ibero-America. The share of technology and solutions increased to 35 percent (33), reflecting the execution of our strategic direction. This devel­op­ment is supported by our differ­enti­ated technology-led offering, and we continue to expand the commercialization of the capabilities we have built across the Group. 

Our security services offering continues to be well received in client segments such as data centers, defense and pharmaceuticals, where long-term partnerships and high-quality security services offerings are increasingly valued. In certain markets and client segments, however, demand trends remain somewhat cautious, resulting in more selective purchasing behavior and longer decision cycles. We are managing this dynamic effectively in North America, while market conditions in certain countries in Europe and Ibero-America remain more frag­mented, which impacted topline growth in the third quarter.

The adjusted operating margin in the third quarter was 8.2 percent (8.3), supported by continued good performance in North America. Operating margins in Europe and Ibero-America were below the strong levels achieved in the third quarter of last year. This was primarily due to the airport security business in Europe which had an impact in the third quarter of –0.2 percent on Group adjusted operating margin. Operating income was in line with last year. For the first nine months of the year, earnings per share increased by 6 percent.

Cash generation remained good, corresponding to 82 percent (106) of operating income in the quarter, and 71 percent (74) for the first nine months of the year. We remain well positioned to achieve our full-year cash flow target of 80–90 percent of operating income before amortization. The net debt to EBITDA ratio was 2.1 (2.2).

THE TRUSTED PARTNER IN INTELLIGENCE-LED SECURITY

Since launching our strategy this summer, I have met with clients across three continents. The response has been very positive, with both existing and prospective clients recognizing the value of our ambition to become the trusted partner in intelligence-led security. They see compelling value in our emphasis on quality and in a more dynamic, intelligence-led approach that combines high-quality security services with technology, data, analytics and Security Risk Management capabilities. While this represents a shift from established industry practices, there is strong support for the direction. Clients increasingly recognize Securitas’ ability to leverage AI, automa­tion and actionable risk intelligence to deliver greater value, and we are already beginning to see early signs of a shift in buying behavior towards intelligence-led security.

As part of the final stage of our strategic assessment program, we expect to have exited the last remaining contracts within the SCIS govern­ment business by the end of October. 

CREATING LONG-TERM SHAREHOLDER VALUE

In conjunction with the launch of our 2030 strategy, we updated the Group’s financial targets, including our target to deliver average annual earnings per share growth of 10 percent over a business cycle. With a clear focus on quality, innovation, and disciplined execution, we are accelerating our transformation and remain confi­dent in our ability to deliver sustain­able earnings growth and create long-term shareholder value.

Magnus Ahlqvist
President and CEO

PRESENTATION OF THE INTERIM REPORT

Analysts and media are invited to participate in a telephone ­conference on October 23, 2026, at 9.30 a.m. (CEST) where President and CEO Magnus Ahlqvist and CFO Matteo Dall’Ora will present the report and answer questions. The ­telephone conference will also be audio cast live via Securitas’ website www.securitas.com 

To follow the audio cast of the telephone conference via the web, please follow the link
www.securitas.com/en/investors/financial-reports-and-presentations/ 

A recorded version of the audio cast will be available at www.securitas.com/en/investors/financial-reports-and-presentations/ after the ­telephone conference.

For further information, please contact: Micaela Sjökvist, Vice President, Investor Relations +46 76 116 7443

ABOUT SECURITAS

Securitas is a world-leading safety and security solutions partner that helps make your world a safer place. Nine decades of deep experience means we see what others miss. By leveraging technology in partnership with our clients, ­combined with an innovative, holistic approach, we’re transforming the security ­industry. With approximately 322 000 employees in 44 markets, we see a ­different world and ­create sustainable value for our clients by protecting what matters most – their people and assets.

Group financial targets

Securitas has the following financial targets:

Average annual earnings per share growth of 10 percent over a business cycle, excluding items affecting comparability and adjusted for changes in exchange rates, with a >10 percent operating margin ambition long-termOperating cash flow of 80–90 percent of operating income before amortizationNet debt to EBITDA below 2.5xDividend policy of 50–60 percent of annual net income over a business cycle, with excess capital returned to shareholders once stra-tegic growth priorities are met

Securitas AB (publ.)
P.O. Box 12307, SE-102 28 Stockholm, Sweden

Visiting address:
Lindhagensplan 70
Telephone: +46 10 470 30 00
Corporate registration number: 556302-7241
www.securitas.com 

This is information that Securitas AB is obliged to make public pursuant to the EU Market Abuse Regulation.
The information was submitted for publication, through the agency of the contact person set out above, at 8.00 a.m. (CEST) on Friday, October 23, 2026.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/securitas/r/securitas-ab-interim-report-q3-2026—january-september,c4414086

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/securitas-ab-interim-report-q3-2026–januaryseptember-302917859.html

Continue Reading

Trending